• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Myriad Genetics Inc. (Amendment)

    2/14/24 8:24:26 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYGN alert in real time by email
    SC 13G/A 1 CamberMYGN13Ga2024.htm PRIMARY DOCUMENT  
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)
     
    Myriad Genetics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.01 per share
    (Title of Class of Securities)
     
    62855J104
    (CUSIP Number)
     
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)62855J104
    ☒  Rule 13d-1(c)
    ☐ Rule 13d-1(d)
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
    Persons who respond to the collection of information contained in this form are not
    required to respond unless the form displays a currently valid OMB control number.
     
    13G
    CUSIP No. 62855J104
    Page 2 of 6
     
                                                 
    1. Names of Reporting Persons.
    Camber Capital Management LP
    42-1693587
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Delaware
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    7,635,000 shares
     
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    7,635,000 shares
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Camber Capital Management LP – 7,635,000 shares
        10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Camber Capital Management LP – 8.5%
    12. Type of Reporting Person
    Camber Capital Management LP – 00 (Limited Partnership)
     
    13G
    CUSIP No.   62855J104
    Page 3 of 6

    1. Names of Reporting Persons.
    Stephen DuBois
    Not applicable
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Stephen DuBois – United States
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    7,635,000 shares
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    7,635,000 shares
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Stephen DuBois – 7,635,000 shares
       10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Stephen DuBois – 8.5%
    12. Type of Reporting Person
    Stephen DuBois – IN
     
    13G
      CUSIP No.   62855J104
    Page 4 of 6
     
     
     
    ITEM 1.
    (a) Name of Issuer:
    Myriad Genetics Inc
     
    (b) Address of Issuer's Principal Executive Offices:
    322 North 2200 West, Salt Lake City, UT 84116
    ITEM 2.
    (a) Name of Person Filing:
    Camber Capital Management LP
    Stephen DuBois
     
    (b) Address of Principal Business Office, or if None, Residence:
    Camber Capital Management LP
    Stephen DuBois
    101 Huntington Avenue
    Suite 2101
    Boston, MA 02199
     
    (c) Citizenship:
    Camber Capital Management LP – Delaware
    Stephen DuBois – United States
     
    (d) Title of Class of Securities:
    Common Stock, par value $0.01 per share
     
    (e) CUSIP Number:
    62855J104
     
     
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
     
     
    (a)
    [_]
    Broker or dealer registered under Section 15 of the Act  (15 U.S.C. 78o).
     
    (b)
    [_]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).   
     
    (c)
    [_]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).   
     
    (d)
    [_]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    [_]
    An investment adviser in accordance with  ss.240.13d-1(b)(1)(ii)(E);   
     
    (f)
    [_]
    An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);   
     
    (g)
    [_]
    A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);   
     
    (h)
    [_]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);   
     
    (i)
    [_]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);   
     
    (j)
    [_]
    Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
     
    ITEM 4. OWNERSHIP.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
    (a) Amount beneficially owned: Camber Capital Management LP – 7,635,000 shares
    Stephen DuBois – 7,635,000 shares
     
    (b) Percent of class: Camber Capital Management LP – 8.5% 
    Stephen DuBois – 8.5%
     
     
    13G
       CUSIP No.   62855J104
    Page 5 of 6
     
    (c) Number of shares as to which such person has:
     
    (i) Sole power to vote or to direct the vote
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (ii) Shared power to vote or to direct the vote
    Camber Capital Management LP – 7,635,000 shares
    Stephen DuBois – 7,635,000 shares
     
    (iii) Sole power to dispose or to direct the disposition of
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (iv) Shared power to dispose or to direct the disposition of
    Camber Capital Management LP – 7,635,000 shares
    Stephen DuBois – 7,635,000 shares
     
     
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
     
     
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
     
    Not applicable
     
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
     
    Not applicable

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
     
    Not applicable
     
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
     
    Not applicable
     
     
    13G
    CUSIP No.   62855J104
    Page 6 of 6
     
     
     
    ITEM 10. CERTIFICATIONS.
    The following certification shall be included if the statement is filed pursuant to S.240.13d-1(c):
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
     
     
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    CAMBER CAPITAL MANAGEMENT LP
    By: /s/Sean George
    Sean George
    Chief Financial Officer
     
    STEPHEN DUBOIS
    By: /s/ Stephen DuBois
    Stephen DuBois, individually
     
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
     
     
    Get the next $MYGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYGN

    DatePrice TargetRatingAnalyst
    5/21/2025$6.00Sector Outperform → Sector Perform
    Scotiabank
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    4/9/2025Buy → Neutral
    Guggenheim
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    2/12/2025$29.00Buy
    Craig Hallum
    12/10/2024$18.00Neutral
    UBS
    12/9/2024$30.00 → $21.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $MYGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

      Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGeneTM screen SALT LAKE CITY, June 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced early access to the FirstGeneTM Multiple Prenatal Screen. The company will begin a large study that will simultaneously deliver reports to patients, while generating clinical validity and clinical utility evidence for this transformational new offering. The FirstGene screen streamlines the

      6/3/25 9:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

      SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, demonstrating successful pan-cancer implementation of Myriad's ultra-sensitive Precise™ MRD Test to detect and monitor ctDNA in patients. The interim results – first shared at the 2025 ASCO Annual Meeting by Tadayoshi Hashimoto, MD, PhD of the NCCHE – achieved 100% baseline detection of ctDNA across tumor types, including those traditionally challenging to asses

      6/2/25 9:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

      SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the MONSTAR-SCREEN-3 study. Myriad will also highlight how its comprehensive portfolio of genetic and tumor genomic testing solutions, coupled with its investments in research and product development, are advancing precision oncology and patient care. An oral abstract (#3007) titled "Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel:

      5/27/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dreismann Heinrich was granted 49,796 shares, increasing direct ownership by 41% to 171,444 units (SEC Form 4)

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      6/6/25 4:05:48 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Bisaro Paul was granted 49,796 shares, increasing direct ownership by 124% to 89,941 units (SEC Form 4)

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      6/6/25 4:05:39 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Davis Mark Steven was granted 24,148 shares, increasing direct ownership by 106% to 46,964 units (SEC Form 4)

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      6/6/25 4:05:23 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care